APA (7th ed.) Citation

H, V., A, C., F, P., M, R., F, N., A, S., . . . J, D. (2026). Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: An international, multicentre, retrospective cohort study. ESMO gastrointestinal oncology, 12, 100335. https://doi.org/10.1016/j.esmogo.2026.100335

Chicago Style (17th ed.) Citation

H, Vandeputte, et al. "Baseline Neutrophil-to-eosinophil Ratio and Neutrophil-to-lymphocyte Ratio as Prognostic Markers in Patients with Unresectable Biliary Tract Cancer Treated with Gemcitabine-cisplatin-durvalumab: An International, Multicentre, Retrospective Cohort Study." ESMO Gastrointestinal Oncology 12 (2026): 100335. https://doi.org/10.1016/j.esmogo.2026.100335.

MLA (9th ed.) Citation

H, Vandeputte, et al. "Baseline Neutrophil-to-eosinophil Ratio and Neutrophil-to-lymphocyte Ratio as Prognostic Markers in Patients with Unresectable Biliary Tract Cancer Treated with Gemcitabine-cisplatin-durvalumab: An International, Multicentre, Retrospective Cohort Study." ESMO Gastrointestinal Oncology, vol. 12, 2026, p. 100335, https://doi.org/10.1016/j.esmogo.2026.100335.